Pedro Herranz Pinto

Drug eruption and exacerbation of psoriasis related to bupropion

Auteur(s) : Cristina GOMEZ-FERNANDEZ1 crisgomezfernandez@hotmail.com, Pedro HERRANZ PINTO1, Beatriz CASADO VERRIER1, Elena SENDAGORTA CUDOS1, Maria Jose BEATO-MERINO2, Mariano CASADO JIMENEZ1 1 University Hospital La Paz, Department of Dermatology, Paseo de la Castellana, 261, 28046. Madrid, Spain 2 University Hospital La Paz, Department of Pathology, Madrid, Spain Bupropion hydrochloride is a psychotropic drug with significant antidepressant effects through the inhibition of re-uptake of norepinephrine [...]

Severe folliculitis with secondary impetiginization in the scalp of a woman treated with panitumumab

Panitumumab is a fully human monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR). It was approved by the Food and Drug Association in 2006, and it is currently considered a useful option in patients with wild-type KRAS tumors when used in combination with chemotherapy for the firstor second-line treatment of metastatic colorectal cancer or as monotherapy for the treatment of metastatic colorectal cancer refractory to chemotherapy. Panitumumab has an acceptable tolerability profile with less systemic toxicities than traditional cytotoxic agents and with lower immunogenetic power than cetuximab, a chimerical monoclonal antibody anti-EGFR. Hypomagnesemia has been reported in a third of patients. Other common systemic adverse events have been described such as fatigue, abdominal pain, anorexia, nausea, diarrhea, constipation, and vomiting. However, the most frequent reported adverse events are cutaneous reactions, experienced by nearly 100% of patients treated with panitumumab. Like other EGFR inhibitors, panitumumab is associated with papulopustular rash, xerosis, pruritus, and nail, hair, and mucosal changes. The severity of dermatologic side effects is associated with the efficacy of treatment, but when they impair life quality, they can hamper compliance and lead to treatment refusal. We present a case of severe folliculitis in the scalp with secondary impetiginization in a 76-year-old woman with metastatic colorectal cancer treated with panitumumab that forced treatment to be withdrawn.

Dermatofitosis atípica en un paciente con SIDA

Resumen —Presentamos el caso de un varon de 37 anos VIH positivo, con nodulos subcutaneos faciales, sin historia previa de infeccion micotica superficial. El estudio histologico mostraba granulomas en dermis centrados por estructuras fungicas. En cultivos repetidos se identifico Microsporum canis. (Actas Dermosifiliogr 2001;92:364-366).

Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study

Abstract Purpose: This study was conducted to examine the relationship between loss of clinical response to anti-tumor necrosis factor (TNF) therapy and the production of anti-drug antibodies (ADAs) and the potential effects of biologic immunogenicity. Materials and methods: This observational, non-interventional, cross-sectional study included patients with moderate-to-severe plaque psoriasis and secondary failure of adalimumab, etanercept and infliximab who were seen in the clinical practice setting. Clinical data and blood samples were collected after patient enrollment at the time that next doses of anti-TNF therapy were scheduled. ADA and serum drug concentrations were detected at a central reference laboratory using ELISA. Results: Among 137 enrolled patients, ADA were identified in 31/65 (48%), 0/47 and 8/19 (42%) of patients treated with adalimumab, etanercept and infliximab, respectively. The presence of ADA was associated with a slightly worse clinical response in adalimumab-treated patients (Physician Global Assessment score: 3.7 vs. 3.2, ADA-positive vs. ADA-negative patients [p < .05]; correlation between serum ADA titer and body surface area: r = .292 [p = .019]). Concomitant DMARDs were not associated with anti-TNF immunogenicity in any treatment group. Conclusions: Additional evidence is needed from studies of anti-TNF therapy in psoriasis for clinicians to gain a better understanding of the impact of immunogenicity on clinical response.

Lesiones Purpúricas en dorso nasal, pabellones auriculares y dedos

Abstract es: Presentamos el caso de un paciente con lesiones purpuricas en regiones acrales. El diagnostico diferencial de este tipo de lesiones incluye patologias mu...